NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization273.54 mln
Float29.51 mln
Earnings Date09/02/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
61.93
Highly suspicious
1-Year Forecast
10.74
Transformational upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.18
Very low leverage
ROE
-42.68
Deeply negative
Business Description
Adagene is a China-based biotechnology company focused on developing antibody-based treatments for cancer. Founded in 2011 and headquartered in Suzhou, the company has built a broad pipeline of drug candidates at various stages of clinical testing, targeting both solid tumors and blood cancers. Its portfolio includes several antibody therapies designed to improve how the immune system attacks cancer cells, with some already in mid-stage clinical trials and others still in early research.
